β³ Fetching live dividend data...
Home βΊ Calculator βΊ HSKA Dividend Calculator 2026
Heska Corporation Β· NASDAQ
Price: $119.99 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
HSKA is not a dividend-focused stock
HSKA pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Heska Corporation (HSKA) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Heska Corporation provides specialized diagnostic and animal health products, predominantly for canine and feline veterinary care markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. Its product line includes a variety of veterinary chemistry analyzers: the Element DC, DCX, and DC5x series, along with the Element RC, RCX, and RC3X systems, all tailored for blood chemistry and electrolyte analysis. For hematological assessments, Heska offers the Element HT5 and scil Vet abc Plus analyzers, capable of measuring blood cell and platelet counts, as well as hemoglobin levels. The company also supplies Element POC analyzers for blood gas and electrolyte testing, Element i immunodiagnostic analyzers, and the Element COAG and Element AIM veterinary analyzers for coagulation studies. Beyond analytical instruments, Heska's offerings extend to advanced imaging and clinical solutions such as HeskaView Telecytology, which provides automated microscopic slide scanning equipment for clinics, and IV infusion pumps. They also distribute digital radiography hardware, including mobile units, sophisticated ultrasound systems, and Cloudbank, a web-based platform for image storage. For rapid, in-clinic detection, point-of-care products are available to identify antigens and antibodies associated with infectious and parasitic diseases in animals. Therapeutic options include Tri-Heart Plus chewable tablets for treating canine heartworm, ascarid, and hookworm infections. The company also specializes in allergy management, offering ALLERCEPT definitive allergen panels for diagnosis and personalized therapy shots or drops. Furthermore, Heska develops a range of vaccines for bovine health. It supplies biological and pharmaceutical products to other animal health companies and offers comprehensive turnkey services encompassing research, licensing, production, labeling, packaging, validation support, and distribution. Products are distributed to veterinarians via a direct telephone sales force, third-party distributors, trade shows, print advertisements, and other strategic partnerships. Founded in 1988, the company was initially known as Paravax, Inc. before rebranding as Heska Corporation in 1995. Its corporate headquarters are located in Loveland, Colorado.
No. Heska Corporation (HSKA) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. HSKA has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open HSKA position with:
Real after-tax yield depends on where you live and how you hold HSKA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
HSKA pays quarterly β 4 times per year. Ex-div: β.
How HSKA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for HSKA sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2023-06-13 | 500 | $120.00 | $60.0K | ||
| D-Return | 2023-06-13 | 2,004 | $120.00 | $240.5K | ||
| A-Award | 2023-06-13 | 4,056 | β | β | ||
| A-Award | 2023-06-13 | 33,111 | β | β | ||
| A-Award | 2022-02-28 | 20,000 | $60.94 | $1.22M | ||
| D-Return | 2023-06-13 | 1,146 | $18.13 | $20.8K | ||
| D-Return | 2023-06-13 | 3,041 | $39.76 | $120.9K | ||
| D-Return | 2023-06-13 | 1,918 | $39.76 | $76.3K | ||
| D-Return | 2023-06-13 | 1,372 | $72.85 | $100.0K | ||
| D-Return | 2023-06-13 | 7,691 | $72.85 | $560.3K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare HSKA with peers: HSKA vs AGTI Β· HSKA vs BKDT Β· HSKA vs CINC
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the HSKA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Heska Corporation (HSKA) is currently trading at $119.99, trading near its 52-week high. It does not currently pay a regular dividend.
Heska Corporation (HSKA) is a healthcare stock trading at $119.99. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever